摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-<2-(diethylamino)ethoxy>iodobenzene | 81233-91-2

中文名称
——
中文别名
——
英文名称
4-<2-(diethylamino)ethoxy>iodobenzene
英文别名
[2-(4-iodophenoxy)ethyl]diethylamine;1-(4'-iodophenoxy)-2-diethylaminoethane;4-(2-diethylaminoethoxy)-iodobenzene;N,N-Diethyl-2-(4-iodophenoxy)ethanamine
4-<2-(diethylamino)ethoxy>iodobenzene化学式
CAS
81233-91-2
化学式
C12H18INO
mdl
——
分子量
319.186
InChiKey
HWDHYBUAFXKQHS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    15
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    12.5
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
    申请人:——
    公开号:US20040259915A1
    公开(公告)日:2004-12-23
    The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them, their use in the treatment and/or prevention of disorders mediated by one or more estrogen receptors and processes for their preparation. The compounds of the invention are useful in the treatment and/or prevention of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.
    本发明涉及新颖的含杂原子四环衍生物、含有它们的药物组合物、它们在治疗和/或预防由一个或多个雌激素受体介导的疾病中的应用,以及它们的制备方法。本发明的化合物在治疗和/或预防与雌激素耗竭相关的疾病中具有用途,例如热潮红、阴道干燥、骨量减少和骨质疏松症;激素敏感性癌症以及乳腺、子宫内膜、宫颈和前列腺的增生;子宫内膜异位症、子宫肌瘤、骨关节炎,以及作为避孕剂,单独使用或与孕激素或孕激素拮抗剂联合使用。
  • [EN] TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS<br/>[FR] HETERO-COMPOSES TETRACYCLIQUES UTILISABLES COMME MODULATEURS DU RECEPTEUR DES OESTROGENES
    申请人:ORTHO MCNEIL PHARM INC
    公开号:WO2003053977A1
    公开(公告)日:2003-07-03
    The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them, their use in the treatment and / or prevention of disorders mediated by one or more estrogen receptors and processes for their preparation. The compounds of the invention are useful in the treatment and / or prevention of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.
    本发明涉及新型含杂原子的四环衍生物、含有它们的药物组合物、它们在治疗和/或预防由一个或多个雌激素受体介导的疾病中的使用以及它们的制备过程。该发明的化合物在治疗和/或预防与雌激素缺乏有关的疾病方面具有用处,例如潮热、阴道干燥、骨质疏松症和骨质疏松症;激素敏感性癌症和乳腺、子宫内膜、子宫颈和前列腺的增生;子宫内膜异位症、子宫肌瘤、骨关节炎以及作为避孕药物,单独使用或与孕激素或孕激素拮抗剂组合使用。
  • Herbicidal heterocyclic and substituted phenyl phenylacetylene amines
    申请人:Ciba-Geigy Corporation
    公开号:US04412856A1
    公开(公告)日:1983-11-01
    The novel compounds of the formula I are useful selective herbicides for postemergence application in crops of cereals, maize and rice. In formula I, ##STR1## A is an unsubstituted or substituted amino group, Q is a C.sub.2 -C.sub.6 alkylene bridge, Y is an oxygen or sulfur atom or an unsubstituted or substituted nitrogen atom, and Z is an unsubstituted or substituted phenyl, naphthyl or heterocyclic radical, which phenyl radical, containing the bridge member Y, can additionally carry one to four further substituents.
    公式I中的新化合物对于小麦、玉米和稻作物的后发生应用是有用的选择性除草剂。在公式I中,##STR1## A是未取代或取代的氨基团,Q是C.sub.2-C.sub.6烷基桥,Y是氧或硫原子或未取代或取代的氮原子,而Z是未取代或取代的苯基,萘基或杂环基团,其中苯基团含有桥接成员Y,还可以携带一到四个进一步的取代基。
  • Identification and Structure−Activity Relationships of Chromene-Derived Selective Estrogen Receptor Modulators for Treatment of Postmenopausal Symptoms
    作者:Nareshkumar Jain、Jiayi Xu、Ramesh M. Kanojia、Fuyong Du、Guo Jian-Zhong、Emmanuel Pacia、Muh-Tsann Lai、Amy Musto、George Allan、Michael Reuman、Xun Li、DoWon Hahn、Martin Cousineau、Sean Peng、David Ritchie、Ronald Russell、Scott Lundeen、Zhihua Sui
    DOI:10.1021/jm900146e
    日期:2009.12.10
    As part of it program aimed at the development of selective estrogen receptor modulators (SERMs), novel chromene scaffolds, benzopyranobenzoxapanes, were discovered. Many compounds showed binding affinity as low as 1.6-200 nM, displayed antagonist behaviors in the MCF-7 human breast adenocarcinoma cell line its well in Ishikawa cell line with IC50 values in the range 0.2-360 nM. On the basis of the side chain substitution, various compounds demonstrated strong inhibitory activity in anti-uterotropic assay. Compound 7-(R) and its major metabolites 5-(R) and 6-(R) were evaluated in several in vivo models of estrogen action. Relative to a full estrogen agonist (ethynyl estradiol) and file SERM raloxifene, 7-(R) wits found to be it potent SERM that behaved its antagonist in the uterus and exhibited estrogen agonistic activity on bone, plasma lipids, hot flush, and vagina. The overall pharmacokinetic profile and stability were Significantly improved compared to those of the phase 2 development compound 9-(R).
  • MOREAU M. -F.; PARRY D.; MICHELOT J.; LABARRE P.; MADELMONT J. -C.; VEYRE+, EUR. J. MED. CHEM., 21,(1986) N 5, 423-431
    作者:MOREAU M. -F.、 PARRY D.、 MICHELOT J.、 LABARRE P.、 MADELMONT J. -C.、 VEYRE+
    DOI:——
    日期:——
查看更多